The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with ...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!